Vivimed Labs Limited · NSE:VIVIMEDLAB
Vivimed Labs — Q3 FY2014 Earnings Presentation
17 slides from Vivimed Labs's earnings presentation, Feb 13, 2014
Slide 1: Q3 and Nine Month FY2014 Earnings Presentation
Vivimed Labs Limited Q3 and Nine Month FY2014 Earnings Presentation February 13, 2014 1 www.vivimedlabs.com © Vivimed Labs Ltd 2010 All rights reserved
Slide 2: Important Notice
Important Notice No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after
Slide 3: Where Chemistry and Quality Matters
Where Chemistry and Quality Matters Unique Business Model Best-in-Class Operations • Uses chemistry to create ingredients which • 12 manufacturing facilities and 5 R&D touch human life on a daily basis centers across the world • Focused on the Health Care, Personal Care, • 4 US FDA approved sites Ho
Slide 4: Business Segments
Business Segments Healthcare Personal Care Home Care Industrials 68% of Q3 FY14 sales 16% of Q3 FY14 sales 13% of Q3 FY14 sales 3% of Q3 FY14 sales • Active • Sun Care • Antimicrobials • Photo Chromic Pharmaceutical • Skin Care • Specialty Dyes Ingredients (API) • Hair Care Intermediates • Imaging C
Slide 5: Consolidated Financial Performance
Consolidated Financial Performance Performance Highlights Q3 FY2014 Revenue Breakup 2.7% Net Sales of Rs. 3,358 million 13.0% 68.0% o Increased 22.4% y-o-y and 9.3% q-o-q 16.3% EBITDA of Rs. 536 million and margins of 16.0% o Increased 44.3% y-o-y o Margin improved 242 bps Net Profit of Rs. 19
Slide 6: Financial Performance
Financial Performance Consolidated Financials Q3 y-o-y Q2 q-o-q Nine Month y-o-y (Rs. million) FY2014 FY2013 Growth (%) FY2014 Growth (%) FY2014 FY2013 Growth (%) Net Sales 3,358 2,744 22.4% 3,073 9.3% 9,870 8,245 19.7% EBITDA 536 371 44.3% 524 2.3% 1,548 1,530 1.2% Margin (%) 16.0% 13.5% 17.0% 15.7
Slide 7: Segment Highlights
Segment Highlights Healthcare Segment Q3 FY14 Revenue: Rs. 2,279 mn • New filings in the API business (DMF/CEP) are expected across various therapy areas over the next 18-24 months 2.9% • Focus on R&D productivity remains as the Company looks forward 19.8% to prospective finished formulations filing
Slide 8: Segment Highlights
Segment Highlights Home Care Segment Q3 FY14 Revenue: Rs. 437 mn 0.0% • Surfactant blends gaining traction in Asia and Brazil; first order 31.0% anticipated from Vietnam • Explore new markets for existing products 69.0% Antimicrobials Speciality intermediates Others Industrials Segment Q3 FY14 Reven
Slide 9: Quarterly Financial Trends
Quarterly Financial Trends Net Sales EBITDA and Margins 524 536 3,439 3,358 488 3,073 452 2,961 371 17.0% Rs. Million 2,744 16.0% 15.3% Rs. Million 13.5% 14.2% Q3 FY13 Q4 FY13 Q1 FY14 Q2 FY14 Q3 FY14 Q3 FY13 Q4 FY13 Q1 FY14 Q2 FY14 Q3 FY14 EBITDA Margin (%) Net Profit and Margins 200 190 169 164 Rs.
Slide 10: Capital Markets
Capital Markets Shareholding Structure Key Institutional Investors 32.3% 37.8% 2.4% 27.5% Promoters FII DII Others Shareholding Pattern Trend Shareholders Dec-12 Mar-13 Jun-13 Sep-13 Dec-13 Promoters1 45.2% 39.7% 39.8% 37.8% 37.8% FII / FDI 16.4% 27.5% 27.4% 27.5% 27.5% DII 0.3% 0.3% 2.5% 2.4% 2.4%
Slide 11: Strategic Direction
Strategic Direction Continue to strengthen engagements with marquee customer base through superior product development and delivery capabilities Where Chemistry and Quality Matters Move up the value chain through vertical integration in Healthcare (R&D to manufacturing of API / FDF / brands) and tar
Slide 12: Global Reach
Global Reach A multinational global platform that provides Vivimed access to markets and significant cost advantage Kashipur, Uttarakhand Haridwar, Uttarakhand Sant Celoni, Spain Lliçà de Vall, Spain Kolkata Cuernavaca, Mexico Bonthapally, Hyderabad Bidar, Karnataka Bolarum, Hyderabad Jeedimetla, Hy
Slide 13: Strong Transnational Management Team
Strong Transnational Management Team Key Management Profile Santosh Varalwar • First generation entrepreneur Managing Director & Chief • Business growth strategy and leadership; Focus on key global client relationships Executive Officer • Previously associated with Shipping Corporation of India Subh
Slide 14: Annexure – Quarterly Consolidated P&L Statement
Annexure – Quarterly Consolidated P&L Statement Profit & Loss Statement (Rs. million) Q1 FY13 Q2 FY13 Q3 FY13 Q4 FY13 Q1 FY14 Q2 FY14 Q3 FY14 Revenues Net Sales / Income from Operations (Net of Excise Duty) 2,725 2,661 2,721 2,981 3,408 3,066 3,353 Other Operating Income 18 97 23 (19) 32 6 5 Total R
Slide 15: Annexure – Segment Highlights
Annexure – Segment Highlights Consolidated Performance Q3 y-o-y Q2 q-o-q Nine Month y-o-y (Rs. million) FY2014 FY2013 Growth (%) FY2014 Growth (%) FY2014 FY2013 Growth (%) Segment Revenue 3,353 2,721 23.2% 3,066 9.3% 9,827 8,107 21.2% Specialty chemicals 1,074 955 12.4% 994 8.1% 3,051 3,529 (13.5)%
Slide 16: Glossary
Glossary • ANDA: Abbreviated New Drug Application • API: Active Pharmaceutical Ingredients • CEP: Certificates of Suitability to the monographs of European Pharmacopoeia • CMO: Contract Manufacturing Organization • DMF: Drug Master File • FDF: Finished Dosage Formulation • H&PC: Home and Personal Ca
Slide 17: Thank You
Thank You Contact Details: Vivimed Labs Limited Veernag Towers, Habsiguda, Hyderabad 500 007 www.vivimedlabs.com Priyanka Mukherjee +91 40 2717 6005 Vivimed Labs Limited priyanka.mukherjee@vivimedlabs.com Saket Somani +91 22 3953 7444 Churchgate Partners saket@churchgatepartnersindia.com